Neumora Therapeutics Newsroom

H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsDec 16 07:31 ET

Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow JonesDec 16 07:26 ET

RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsDec 5 11:31 ET

Neumora Therapeutics Analyst Ratings

BenzingaNov 22 11:58 ET

RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsNov 22 07:32 ET

Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)

TipRanksNov 22 06:57 ET

Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating

Moomoo NewsNov 14 03:32 ET

RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsNov 13 07:32 ET

H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsNov 13 06:31 ET

Neumora Therapeutics, Inc.: Strategic Advancements and Unique Efficacy in MDD Trials Drive Buy Rating

TipRanksNov 13 06:28 ET

Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsNov 13 05:38 ET

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)

TipRanksNov 13 05:22 ET

Neumora Therapeutics Analyst Ratings

BenzingaNov 13 05:10 ET

Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating

Moomoo NewsNov 12 03:32 ET

Mizuho Securities Remains a Buy on Neumora Therapeutics, Inc. (NMRA)

TipRanksNov 12 02:51 ET

Neumora Therapeutics Price Target Cut to $15.00/Share From $18.00 by JP Morgan

Dow JonesNov 5 07:26 ET

Neumora Therapeutics Analyst Ratings

BenzingaNov 5 07:17 ET

J.P. Morgan Initiates Neumora Therapeutics(NMRA.US) With Hold Rating, Announces Target Price $15

Moomoo NewsNov 5 05:33 ET

Cautious Hold on Neumora Therapeutics Amid Uncertainty in KOASTAL-1 Trial Outcomes

TipRanksNov 5 05:11 ET

Neumora Therapeutics Downgraded to Neutral From Overweight at JPMorgan

TipRanksNov 5 04:58 ET